Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of enzalutamide on oxycodone pharmacokinetics in men with prostate cancer
NL-OMON51266Phase 4Active, not recruiting
- Sponsor
- Deventer Ziekenhuis
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of enzalutamide and oxycodone in prostate cancer (PCa) (2 cohorts), sponsored by Deventer Ziekenhuis. Primary endpoints: Difference in oxycodone Cmax and Difference in oxycodone AUC0-t. Started Aug 2021; status: active, not recruiting.
02
Drugs
enzalutamideoxycodone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON51266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51266.